Edition:
United States

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

17.39USD
10:18am EST
Change (% chg)

$0.09 (+0.52%)
Prev Close
$17.30
Open
$17.29
Day's High
$17.53
Day's Low
$17.07
Volume
65,264
Avg. Vol
170,436
52-wk High
$20.89
52-wk Low
$7.37

Latest Key Developments (Source: Significant Developments)

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 04:30pm EST 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

Collegium To License Rights To Commercialize Nucynta Franchise
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE.COLLEGIUM PHARMACEUTICAL INC - DEAL IS IMMEDIATELY ACCRETIVE.COLLEGIUM PHARMACEUTICAL INC - ENTERED INTO A DEFINITIVE COMMERCIALIZATION AGREEMENT WITH DEPOMED.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY A MINIMUM ANNUAL LICENSE FEE OF $135.0 MILLION PAID QUARTERLY IN ARREARS.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL ALSO PAY DOUBLE-DIGIT ROYALTIES ON NET SALES ABOVE $233.0 MILLION PER YEAR.COLLEGIUM PHARMACEUTICAL - AFTER 12 MONTHS, CO MAY TERMINATE AGREEMENT WITH TWELVE MONTHS' NOTICE AND PAYMENT OF A $25.0 MILLION TERMINATION FEE.COLLEGIUM PHARMACEUTICAL INC - AFTER FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY DOUBLE-DIGIT ROYALTIES ON ALL NET SALES.COLLEGIUM PHARMACEUTICAL INC - TRANSACTION HAS BEEN APPROVED BY COLLEGIUM'S AND DEPOMED'S BOARD OF DIRECTORS.COLLEGIUM PHARMACEUTICAL INC - EXPECTS TO SUPPORT NUCYNTA FRANCHISE WITH ITS EXISTING RETAIL AND HOSPITAL FIELD FORCES.COLLEGIUM PHARMACEUTICAL INC - WILL RECEIVE AN EXCLUSIVE SUBLICENSE TO COMMERCIALIZE NUCYNTA AND NUCYNTA ER IN UNITED STATES.  Full Article

Collegium reports third quarter loss of $0.45 per share
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Collegium Pharmaceutical Inc :Collegium reports third quarter financial results and provides corporate update.Q3 loss per share $0.45.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Collegium receives FDA approval for sNDA for Xtampza® ER
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Collegium Pharmaceutical Inc :Collegium receives FDA approval for sNDA for Xtampza® ER.  Full Article

Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER
Monday, 6 Nov 2017 08:45am EST 

Nov 6 (Reuters) - Collegium Pharmaceutical Inc :Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER.Collegium Pharmaceutical - ‍FDA hasn't requested any additional scientific information or data regarding co's snda for Xtampza ER​.  Full Article

Collegium reports Q2 loss per share $0.72
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Collegium Pharmaceutical Inc -:Collegium reports second quarter financial results and provides corporate update.Q2 loss per share $0.72.Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.Collegium-‍believe existing cash, expected cash from commercialization of xtampza er will fund operating expenses,debt service,capex requirements into 2019​.  Full Article

Collegium reports Q1 loss per share $0.79
Wednesday, 10 May 2017 04:01pm EDT 

May 10 (Reuters) - Collegium Pharmaceutical Inc :Collegium reports first quarter financial results and provides corporate update.Q1 loss per share $0.79.Q1 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Collegium Pharmaceutical Inc- Cash and cash equivalents of $129.6 million as of March 31, 2017 compared to $153.2 million as of December 31, 2016.Q2 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.  Full Article

Collegium Pharmaceutical announces expanded managed care coverage
Monday, 3 Apr 2017 04:01pm EDT 

Collegium Pharmaceutical Inc : Collegium Pharmaceutical announces expanded managed care coverage for Xtampza ER for medicare part D patients .Collegium Pharmaceutical - effective April 1, Xtampza ER is exclusive branded oxycodone extended-release product for organization's part D plan designs.  Full Article

Collegium Q4 loss per share $1.02
Thursday, 9 Mar 2017 04:01pm EST 

Collegium Pharmaceutical Inc : Collegium reports fourth quarter financial results and provides corporate update . Q4 loss per share $1.02 . Q4 earnings per share view $-1.07 -- Thomson Reuters I/B/E/S .Collegium Pharma -believe existing cash resources, with expected cash inflows from commercialization of xtampza ER to fund expenses, into 2019.  Full Article